TL/DR –
Novo Nordisk CEO Mike Doustdar states that the obesity market has potential for significant growth, with millions of Americans potentially eligible for treatment. Doustdar noted the underutilization of GLP-1 drugs, which could not only assist with weight loss but also contribute to broader economic benefits through a healthier, smaller population consuming less medication. He also highlighted the potential productivity gains from healthier people returning to work.
Novo Nordisk’s AI Collaboration Accelerates Drug Discovery
Novo Nordisk’s CEO Mike Doustdar discussed how the company is harnessing artificial intelligence (AI) to enhance drug discovery and development, particularly in the obesity treatment sector. Despite the transformative impact of weight-loss drugs on the market, Doustdar believes there is much more potential to be explored, with tens of millions of US citizens potentially eligible for treatment.
In an interview with FOX Business’ Cheryl Casone on “Mornings with Maria“, Doustdar discussed the adoption and economic impact of GLP-1 drugs and the company’s outlook for medicines, including the promising weight-loss drug Wegovy.
Doustdar emphasized that despite the significant population suffering from obesity and the limited use of GLP-1 medications, there’s ample opportunity for growth. With over 100 million people in the US suffering from obesity, and only around 10-15% of them using a GLP-1, the runway for these drugs is long.
Beyond weight loss, Doustdar believes wider use of these drugs could help Americans save on healthcare costs while contributing to broader economic benefits. These benefits can be achieved through medication use optimization. He used insulin, another product sold by Novo Nordisk, as an example of how dosage can vary with body size.
He also highlighted the potential value of healthier people returning to work and becoming more productive. Doustdar argued that the benefits of these drugs could extend beyond the number on a scale, improving the overall health and productivity of the population.
For more information, click here to stay up to date with Novo Nordisk’s advances on FOX Business.
—
Read More Health & Wellness News ; US News